Settled!?
25/06/20 -"Bayer’s management will take a lot of money off its hands trying to settle three litigations in the US, of which the RoundUp one will be the most expensive. With this move, Bayer lifts some ..."
Pages
74
Language
English
Published on
25/06/20
You may also be interested by these reports :
19/08/26
The Q2 sales were ahead of expectations, though profitability was in line with consensus. Strong growth for the migraine drug Vyepti, ...
18/08/26
The H1 results exceeded expectations, backed by strong growth in Bimzelx and other key products. Consequently, the management revised the full-year ...
17/08/26
The Q2/H1 results surpassed expectations, again driven by the Biosimilars growth engine, as Generics posted muted growth. Also, the management ...
14/08/26
The Q2 results exceeded consensus estimates, driven by a healthy showing from Crop Science, whereas the growth for the other two businesses was ...